Sepsis is one of medicine’s most urgent emergencies because a small delay in treatment can quickly turn a manageable infection into organ failure and death. The problem is that doctors often do not know, at first, which bacterium is causing a bloodstream infection, so they typically start with broad-spectrum antibiotics that target many microbes at once. That approach can save lives, but it also exposes patients to drugs they may not need and adds to the wider problem of antibiotic resistance. Researchers in Sweden now say they have built a faster path to an answer by combining microfluidics, the control of tiny amounts of liquid in miniature channels, with AI-assisted imaging. The team, from KTH Royal Institute of Technology and Uppsala University, reported a system that can confirm bacterial infection in about two hours and move toward identifying the right antibiotic in roughly four to six hours. In laboratory tests with blood samples seeded with bacteria, the method detected E. coli, K. pneumoniae, and E. faecalis at levels relevant to real clinical cases. If the approach holds up in hospital use, it could shorten one of the most consequential waiting periods in emergency care and help doctors treat sepsis with more precision.
Why Speed Matters in Sepsis
Sepsis happens when the body’s response to infection becomes dangerously dysregulated, damaging its own tissues and organs. In severe cases, patients can slip into septic shock, where blood pressure drops and the risk of death rises sharply.
That is why clinicians often say sepsis care is a race against time. Lead author Henar Marino Miguelez noted that for patients in septic shock, every hour of delayed treatment can reduce survival by about eight percent.
The Bottleneck in Today’s Testing
The standard way to diagnose bloodstream infections is still based on blood culture, in which a patient’s blood is incubated so any bacteria present can grow to detectable levels. It is reliable, but growth takes time, and hospital labs may need at least a day before the first useful clues appear.
That delay creates a difficult compromise. Doctors must often begin treatment before they know the culprit, so they reach for broad-spectrum antibiotics rather than a narrow drug tailored to a specific pathogen.
As Wouter van der Wijngaart of KTH put it, hospitals can take two to four days before they are sure which antibiotic is best for a bloodstream infection. The Swedish team’s goal is to shrink that timeline to just a few hours.
How the New System Works
The first step is a clever form of centrifugation, which uses spinning force to separate materials by their physical properties. Here, the blood sample is spun on top of an agent that makes bacteria float upward while heavier blood cells settle downward.
The result is a clear liquid layer containing bacteria but not blood cells. That matters because blood cells can interfere with imaging and make it harder for miniature fluidic systems to handle the sample cleanly.
Once isolated, that liquid is fed into a microfluidic chip. These chips are essentially tiny laboratories etched with narrow channels that can move and process microscopic volumes of liquid quickly and with high control.
Where AI Comes In
After the sample enters the chip, the system uses automated microscopy to look for signs of bacteria. Instead of relying only on a human expert peering through a microscope, the images are analyzed with software trained by artificial intelligence.
In practical terms, the AI helps the system recognize bacterial patterns faster and more consistently than a purely manual workflow. According to the researchers, that allows a clinic to confirm a bacterial infection in as little as two hours.
The full promise is not just early detection, but faster guidance on treatment. Van der Wijngaart said the team is working toward determining the right antibiotic in about four to six hours, far quicker than conventional routines.
What the Tests Showed
The researchers evaluated the system using blood samples spiked with known bacteria. In those experiments, it detected Escherichia coli, Klebsiella pneumoniae, and Enterococcus faecalis, all important causes of serious infection.
Just as important, the platform worked at low bacterial concentrations, down to roughly 7 to 32 colony-forming units per millilitre. That term refers to the estimated number of living bacterial cells capable of growing into colonies, and low counts are common in real bloodstream infections, making sensitivity essential.
The work was reported in Digital Medicine, and the team described it as a faster alternative to the culturing methods that hospitals routinely use for suspected bloodstream infections. The key advantage is not that it replaces every step of microbiology, but that it appears to move the earliest and most critical decisions much closer to the bedside timeline doctors actually need.
Why This Matters
Today, broad-spectrum antibiotics are often started as a safety measure when sepsis is suspected. That can be lifesaving, but it is also a blunt instrument: these drugs can be toxic, disturb healthy gut bacteria, and encourage the rise of antibiotic-resistant strains.
A faster test could let clinicians switch sooner from a broad guess to a targeted therapy. That would be better for the patient in front of them and, over time, better for public health by reducing unnecessary antibiotic exposure.
There is also a workflow benefit. A rapid system that combines sample preparation, chip-based handling, and AI image analysis could ease pressure on hospital laboratories and help standardize difficult early-stage testing.
What Comes Next
The reported results come from controlled tests using blood samples seeded with bacteria, which is an important step but not the same as full validation in busy hospitals with complex patient cases. The next challenge will be showing that the method performs reliably across the messy variability of real clinical samples and integrates smoothly into routine care.
Even so, the concept is compelling because it attacks the sepsis problem at exactly the point where medicine is weakest: the long wait between suspicion and certainty. If future studies confirm the early results, AI-guided microfluidic diagnostics could help turn sepsis treatment from an anxious guessing game into a faster, more precise response.